IDEXX Laboratories Inc (IDXX)
475.72
-1.94
(-0.41%)
USD |
NASDAQ |
Apr 19, 13:16
IDEXX Laboratories Revenue (Quarterly): 901.60M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 901.60M |
| September 30, 2023 | 915.53M |
| June 30, 2023 | 943.63M |
| March 31, 2023 | 900.20M |
| December 31, 2022 | 828.57M |
| September 30, 2022 | 841.66M |
| June 30, 2022 | 860.55M |
| March 31, 2022 | 836.55M |
| December 31, 2021 | 801.09M |
| September 30, 2021 | 810.42M |
| June 30, 2021 | 826.14M |
| March 31, 2021 | 777.71M |
| December 31, 2020 | 720.94M |
| September 30, 2020 | 721.79M |
| June 30, 2020 | 637.59M |
| March 31, 2020 | 626.34M |
| December 31, 2019 | 605.45M |
| September 30, 2019 | 605.30M |
| June 30, 2019 | 620.10M |
| March 31, 2019 | 576.06M |
| December 31, 2018 | 549.39M |
| September 30, 2018 | 545.45M |
| June 30, 2018 | 580.75M |
| March 31, 2018 | 537.66M |
| December 31, 2017 | 506.12M |
| Date | Value |
|---|---|
| September 30, 2017 | 491.98M |
| June 30, 2017 | 508.94M |
| March 31, 2017 | 462.02M |
| December 31, 2016 | 443.00M |
| September 30, 2016 | 448.31M |
| June 30, 2016 | 466.57M |
| March 31, 2016 | 417.55M |
| December 31, 2015 | 399.68M |
| September 30, 2015 | 406.39M |
| June 30, 2015 | 413.34M |
| March 31, 2015 | 382.48M |
| December 31, 2014 | 351.96M |
| September 30, 2014 | 383.52M |
| June 30, 2014 | 390.12M |
| March 31, 2014 | 360.20M |
| December 31, 2013 | 354.07M |
| September 30, 2013 | 338.30M |
| June 30, 2013 | 352.58M |
| March 31, 2013 | 332.11M |
| December 31, 2012 | 319.54M |
| September 30, 2012 | 315.48M |
| June 30, 2012 | 335.65M |
| March 31, 2012 | 322.68M |
| December 31, 2011 | 307.20M |
| September 30, 2011 | 300.95M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
605.30M
Minimum
Sep 2019
943.63M
Maximum
Jun 2023
777.95M
Average
810.42M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| Stryker Corp | 5.815B |
| Haemonetics Corp | 336.25M |
| Align Technology Inc | 956.73M |
| Edwards Lifesciences Corp | 1.534B |
| ACADIA Pharmaceuticals Inc | 231.04M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 194.52M |
| Total Expenses (Quarterly) | 656.30M |
| EPS Diluted (Quarterly) | 2.32 |
| Enterprise Value | 40.18B |
| Gross Profit Margin (Quarterly) | 58.36% |
| Profit Margin (Quarterly) | 21.58% |
| Earnings Yield | 2.12% |
| Operating Earnings Yield | 2.75% |
| Normalized Earnings Yield | 2.117 |